Background: Platinum-resistant ovarian cancer remains a major therapeutic challenge, with limited benefit from currently available cytotoxic agents. Elenagen is a newly developed plasmid DNA-based anticancer agent that encodes p62/SQSTM1 protein, a multifunctional adaptor protein involved in selective autophagy, signal transduction, and modulation of the inflammatory response. We previously reported the progression-free survival outcomes of patients with platinum-resistant ovarian cancer treated…
Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in platinum-resistant ovarian cancer patients: a phase II trial
medRxiv Oncology | | Krasny, S., Baranau, Y., Bakin, E., Polyakov, S., Streltsova, O., Zharkova, E., Filimonava, A., Levin, G., Gabai, V., Shneider, A.
Topics: blood-cancer, ovarian-cancer, chemotherapy, clinical-trials